GENB Earnings Results and History
Generate Biomedicines, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.68 vs −$0.56 est −22.2%
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- Collaboration revenue fell to $4.2 million from $9.6 million a year earlier as Amgen and Novartis work nears completion.
- R&D expense rose to $82.3 million, driven by the GB-0895 Phase 3 SOLAIRIA trials in severe asthma.
Filings and dates
SEC EDGAR- Feb 11, 2027Next earnings reportexpected
- Nov 12, 2026Earnings release, Q3 20268-K Press release
Also see GENB institutional ownership and the earnings calendar.
GENB earnings FAQ
What were GENB's latest earnings?
For Q3 2026 Generate Biomedicines, Inc. reported, GAAP EPS of -$0.68. The results were filed with the SEC on Nov 12, 2026.
When is GENB's next earnings date?
Generate Biomedicines, Inc. is expected to report on Feb 11, 2027. Dates can move until the company confirms them.
Where do these numbers come from?
Results, guidance and financials come from Generate Biomedicines, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.